What is Altimmune's stock issuance proceeds?

Altimmune (ALT) reported stock issuance proceeds of $8.74M in Q1 2026.

How has Altimmune's stock issuance proceeds changed year-over-year?

Altimmune's stock issuance proceeds decreased by 74.8% year-over-year, from $34.75M to $8.74M.

What is the long-term trend for Altimmune's stock issuance proceeds?

Over 4 years (2021 to 2025), Altimmune's stock issuance proceeds has grown at a 28.0% compound annual growth rate (CAGR), from $64.82M to $173.73M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Altimmune ALT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co.MRK

$157M+726%

Viking TherapeuticsVKTX

$450K+28.9%

Wave Life SciencesWVE

$1.93M-21.1%

Delcath SystemsDCTH

$389K+63.4%

MeiraGTx Holdings plcMGTX

$14.03M+213%

Madrigal Pharmaceuticals, Inc.MDGL

——

Other financials

Income statement

See full

Revenue$26.0K+420%

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation

See full

Market cap$558.14M-2.1%

Enterprise value$495.27M-5.0%

P/S13,613.2×-24,380×

Profitability

See full

Operating margin-230,461%-82,087pp

Net margin-214,861%-76,057pp

FCF margin-17,806.8%-110,030pp

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Altimmune's stock issuance proceeds?: Altimmune (ALT) reported stock issuance proceeds of $8.74M in Q1 2026.
How has Altimmune's stock issuance proceeds changed year-over-year?: Altimmune's stock issuance proceeds decreased by 74.8% year-over-year, from $34.75M to $8.74M.
What is the long-term trend for Altimmune's stock issuance proceeds?: Over 4 years (2021 to 2025), Altimmune's stock issuance proceeds has grown at a 28.0% compound annual growth rate (CAGR), from $64.82M to $173.73M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.